CEACAM6 and neoplasm: CEACAM6 mAbs with paclitaxel treatment markedly decreased tumor growth by 40% to 80% compared to CEACAM6 mAbs alone and were more effective in CEACAM6-targeting albumin-based nanoparticles [188,189].